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Killer cell immunoglobulin-like receptors (KIR) regulate immune responses in NK and CD8+ T
cells via interaction with HLA ligands. KIR genes, including KIR2DS1, KIR3DL1, and KIR3DS1
have previously been implicated in psoriasis susceptibility. However, these previous studies
were constrained to small sample sizes, in part due to the time and expense required for direct
genotyping of KIR genes. Here, we implemented KIR*IMP to impute KIR copy number from
single-nucleotide polymorphisms (SNPs) on chromosome 19 in the discovery cohort
(n=11,912) from the PAGE consortium, University of California San Francisco, and the
University of Dundee, and in a replication cohort (n=66,357) from Kaiser Permanente
Northern California. Stratified multivariate logistic regression that accounted for patient
ancestry and high-risk HLA alleles revealed that KIR2DL2 copy number was significantly
associated with psoriasis in the discovery cohort (p ≤ 0.05). The KIR2DL2 copy number
association was replicated in the Kaiser Permanente replication cohort. This is the firstorg June 2021 | Volume 12 | Article 6843261
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Frontiers in Immunology | www.frontiersin.reported association of KIR2DL2 copy number with psoriasis and highlights the importance of
KIR genetics in the pathogenesis of psoriasis.Keywords: psoriasis, KIR, HLA, imputation, genetics, autoimmunityINTRODUCTION
Psoriasis is an inflammatory, immune-mediated skin disease
affecting approximately 3% of the US population (1). Psoriasis
has been associated with numerous systemic comorbidities
including psoriatic arthritis, atherosclerosis, metabolic
syndrome, type 2 diabetes, non-alcoholic fatty liver disease,
and inflammatory bowel disease (2, 3). Psoriasis is known to
be a complex heritable disease with over 64 genetic loci identified
by genome-wide association studies in European and Asian
cohorts (4, 5). The locus demonstrating the strongest effect on
risk is the MHC region, with several alleles ofHLA-C andHLA-B
conferring a 2-4-fold increased risk of psoriasis (6). There are
multiple biological mechanisms by which psoriasis-associated
HLA alleles can increase disease susceptibility. We have
previously shown (7), and other groups have confirmed (8),
that there are canonical amino acid residues within the peptide
binding groove of HLA-C and HLA-B that strongly associate
with psoriasis, suggesting that HLA alleles with these residues
may bind psoriasis autoantigens, several of which have been
described (9, 10). HLA-B allotypes also bind to regulatory
leukocyte immunoglobulin-like receptors (LILRs) on antigen
presenting cells with differential affinity, which we have also
shown associates with psoriasis susceptibility (11). Alternatively,
class I MHC molecules including HLA-C and HLA-B may serve
as ligands for killer immunoglobulin-like receptors (KIR), which
are expressed on both natural killer (NK) cells and CD8+ T cells.
KIRs comprise a number of activating and inhibitory
receptors that help regulate NK and CD8+ T cell responses
and have been implicated in a number of clinical conditions,
including susceptibility to a number of autoimmune disorders,
viral infections, spontaneous abortion, and certain cancers (12).
KIRs are encoded by a cluster of genes located on chromosome
19q13.4 (13) and different KIR haplotypes vary in the presence or
absence of individual KIR genes, leading to KIR copy number
variation in individuals. Moreover, much like the genes for their
corresponding HLA ligands, KIR genes are highly multi-allelic
and not easily amenable to direct genotyping via inexpensive
genome-wide association study (GWAS) SNP panels. As a result,
KIR copy number typing or allelic typing typically necessitates
costly Sanger or next-generation sequencing.
Although a number of prior genetic studies have suggested
KIR associations with psoriasis, including KIR2DS1 (12),
KIR3DL1 (14, 15), and KIR3DS1 (7) these studies have been
hampered by relative small sample sizes due to the expense of
KIR sequencing. Over the last decade, efficient and accurate
methods to impute HLA alleles from GWAS panels have been
developed (16, 17) and have been leveraged to great success in
several large-scale studies (7, 18, 19). More recently, we
developed an accurate method to impute KIR copy numberorg 2(KIR CN) using SNP data from GWAS arrays (20). In this
present study we have imputed HLA alleles and KIR CN into
large-scale psoriasis GWAS datasets totaling 10,066 cases and
68,203 controls (Figure 1). We used a discovery cohort
(comprised of samples from UCSF, the University of Dundee,
and the Population Architecture Using Genomics and
Epidemiology (PAGE) consortium—referred to henceforth as
PAGE+) to perform association testing of psoriasis with KIR CN
alone, HLA ligands alone, and in a joint HLA-KIR CN model,
and identified an association of psoriasis with KIR2DL2 in HLA
C1/C2 heterozygotes. The KIR2DL2 CN association was
replicated in an independent dataset, which consists of samples
from Kaiser Permanente Northern California (KP). To our
knowledge, this is the largest examination of HLA-KIR in any
human disease to-date, and highlights the importance of KIR
genetics in the pathogenesis of psoriasis.METHODS
Sample Collection and Genotyping
UCSF and University of Dundee
Psoriasis patient and healthy control saliva samples were obtained at
UCSF (21) and theUniversity ofDundee (22). Librarieswere prepared
from these saliva samples and genotyped on the Affymetrix UK
Biobank platform. After genotyping, SNPs were called with
Affymetrix Power Tools v 1.18.0 (Affymetrix Power Tools. http://
www.affymetrix.com/partners_programs/programs/developer/tools/
powertools.affx) using the recommendedparameters in theAffymetrix
Best Practices Workflow (Affymetrix, “Axiom® Genotyping Solution
Data Analysis Guide”, 2014. http://media.affymetrix.com/support/
downloads/manuals/axiom_genotyping_solution_analysis_guide.
pdf) (details in Supplementary Methods).
PAGE Consortium
We refer the reader to Tsoi et al. (23) for more details on the
phenotyping or genotyping of the samples from the
PAGE consortium.
Principal Component Analysis
We implemented Eigenstrat (24) using 1,732 SNPs to perform
principal components analysis (PCA) to compute the top 10
principal components (PCs) (details in Supplementary Methods).
HLA Allele and KIR CN Imputation
After initial quality control and filtering of the genotype data
from chromosomes 6 and 19, HLA-B and -C alleles were
imputed using HLA*IMP:03 (16) while KIR CN imputation
was performed using KIR*IMP (20). We used a posterior
probability of 0.6 as a cutoff for poor quality HLA alleleJune 2021 | Volume 12 | Article 684326
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the remaining samples was > 0.95. As per recommendations
from Motyer et al. (25), we did not apply a KIR CN call filter
based on the posterior probability of the call.
We have also recently implemented a KIR typing algorithm
that utilizes next-generation sequencing (NGS) data to call KIR
types (26). 826 of the 954 samples we genotyped on the UK
Biobank Affymetrix chip were also submitted for NGS
sequencing (27) and had successful KIR typing. Across the 6
KIR genes we imputed, the concordance with the NGS-based
KIR typing was 91.2%, demonstrating that KIR*IMP imputation
is a reliable method for imputing KIR genes. The only KIR gene
to have a concordance less than 90% was KIR2DL1 (76%).
Statistical Modeling: Logistic Regression
Models and Meta-Analysis
All data preparation and modeling was performed using R (28).
The KIR CN only models included a factor variable (0, 1, or 2
copies) for each of the 6 KIR genes tested (KIR2DL1, KIR2DL2,
KIR2DS1, KIR2DS4, KIR3DL1, and KIR3DS1). The HLA only
models included a variable to indicate the presence of each of the 5
HLA ligand genotypes (HLA-C1, HLA-C2, HLA-Bw4, HLA-Bw4-
80I, and HLA-Bw4-80T) as well as the presence of the known
high-risk psoriasis alleles, HLA-C*06:02 and HLA-C*12:03 (8). ToFrontiers in Immunology | www.frontiersin.org 3adjust for the effect of population stratification, we also included
the top 10 principal components in each model that we tested as
covariates. Fixed-effects meta-analysis was performed using the
“meta” package in R by Schwarzer et al. (29).
In this study we examined the PAGE+ cohort (discovery),
which consists of 7198 cases and 4714 controls of European
descent from UCSF, the University of Dundee, and the PAGE
consortium (23), and 2) the Kaiser Permanente (KP) cohort
(replication), which consists of 2868 cases and 63489 controls of
European from the Northern California Kaiser Permanente
Health system (Table 1). We used HLA*IMP:03 (16) to
perform imputation of class I HLA alleles (HLA-A, -B, and -C)
to two field (4 digit) resolution and used KIR*IMP (20) to
perform imputation of KIR copy number.RESULTS
Association Testing of KIR Copy Number
With Psoriasis
To determine whether copy number of KIR2DL1, KIR2DL2,
KIR2DS1, KIR2DS4, KIR3DL1, or KIR3DS1 were associated with
psoriasis independent of HLA ligands, we imputed the copy
number (0, 1, or 2 copies) of these genes in the PAGE+ cohort ofFIGURE 1 | Methods flowchart. Flowchart outlining 1) the collection of SNP data from the PAGE consortium and KP as well as the genotyping of SNPs from the
UCSF and University of Dundee datasets 2) QC, phasing, and imputation of HLA alleles and KIR CN 3) PCA using ancestry informative SNPs 4) merging of HLA,
KIR, and PCA data 5) Association testing in the discovery cohort followed by replication and meta-analysis.June 2021 | Volume 12 | Article 684326
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using a general (0 vs 1 vs 2 copies) logistic regression model
adjusted for the top 10 principal components (PCs) of ancestry.
At a nominal p-value threshold of 0.05, we found that none of the
six KIR genes tested were significantly associated with psoriasis
(Figure 2). A dominant (0 vs 1 or 2 copies) logistic regression
model adjusted for the top 10 PCs also yielded no significant
associations with psoriasis (see Supplementary Table 1 for
full results).
Association Testing of HLA Ligands
With Psoriasis
As KIR are known to bind the defined HLA ligands HLA-C1,
HLA-C2, and HLA-Bw4 (Table 2), we examined whether these
HLA ligands were associated with psoriasis in the PAGE+ cohort
using a general and dominant logistic regression model adjusted
for the top 10 PCs. We found that all three HLA ligands wereFrontiers in Immunology | www.frontiersin.org 4significantly associated with psoriasis in the general and
dominant model when not adjusting for any individual HLA
alleles (Supplementary Table 2). However, after adjustment for
the top psoriasis allele HLA-C*06:02, these associations were
altered in the dominant model, with only HLA-C2 and HLA-
Bw4 remaining significant. The HLA-Bw4 ligand may be further
subdivided into HLA-Bw4-80I alleles and HLA-Bw4-80T alleles,
which display differential binding affinity to KIR3DL1 (44). We
found that the association of HLA-Bw4 with psoriasis, after
adjustment with HLA-C*06:02, was driven by HLA-Bw4-80I and
not by HLA-Bw4-80T (Figure 3; see Supplementary Table 2 for
full results of models not adjusted for HLA-Cw6).
KIR Copy Number Models Stratified
on Their HLA Ligands Reveals Inhibitory
KIR2DL2 Copy Number Is Associated
With Psoriasis
Because of the known biologic interaction between KIR and
HLA ligands, we then tested joint models for KIR CN restricted
to cases and controls who were positive for cognate HLA
ligands (Table 2). Of the six KIRs and their respective HLA
ligands, we found that having two copies of KIR2DL2 (odds
ratio (OR) = 1.25, 95% confidence interval (CI) [1.05 – 1.50])
in cases and controls who were HLA-C1/C2 heterozygous, was
significantly associated with psoriasis in the PAGE+ cohort.
KIR2DL2 is known to biologically bind HLA-C1 and weakly
interact with HLA-C2 (35). Sensitivity testing revealed that
KIR2DL2 remained associated with psoriasis even after
including HLA-C*06:02 and HLA-C*12:03 alleles as covariates
in the model, two individual HLA alleles that have beenFIGURE 2 | KIR copy number alone is not associated with psoriasis. Plot of ORs estimated from association testing of KIR CN with psoriasis after adjusting for the




University of Dundee 763 676
PAGE-Germany 2178 543
PAGE-Estonia 856 1250
PAGE-North America 2654 1291
Discovery total 7198 4714
Replication cohort
Kaiser Permanente 2868 63489
Discovery and replication total 10066 68203June 2021 | Volume 12 | Article 684326
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Supplementary Table 3 for full results). To confirm this
result in an independent dataset, we tested the KIR2DL2 CN
model in HLA-C1/C2 heterozygotes and adjusted for HLA-
C*06:02 and HLA-C*12:03 in the KP dataset and found a
significant result (KIR2DL2 CN = 1: OR = 1.17, CI [1.03;
1.33]; KIR2DL2 CN = 2: OR = 1.44, CI [1.02; 2.04]) (Figure 5).
Meta-Analysis of KIR2DL2 in the PAGE
and KP Cohorts
Finally, we performed a meta-analysis of the model that was
statistically significant in both the PAGE+ and KP cohorts (meta-
analysis 1: KIR2DL2 CN = 2, HLA-C1/C2, and adjusted for HLA-
C*06:02 andHLA-C*12:03) as well as models that were statistically
significant in only the KP cohort (meta-analysis 2: KIR2DL2 CN =
1, HLA-C1/C2, and adjusted for HLA-C*06:02 and HLA-C*12:03)
(Figure 6). For each meta-analysis, a fixed-effects model was
implemented as there was no evidence of heterogeneity between
the two cohorts (p > 0.05). With two copies of KIR2DL2 (meta-
analysis 1), the fixed-effects odds ratio was 1.33 [95% CI (1.13 –
1.57)] while the effect size was still in the same direction but lower
with only one copy of KIR2DL2 (meta-analysis 2), with a fixed-
effects odds ratio of 1.13 [95% CI (1.03 – 1.23)].DISCUSSION
HLA and KIR Imputation Into GWAS
Datasets
While several studies of the role of HLA and KIR have been
conducted over the last several decades, most of these studiesFrontiers in Immunology | www.frontiersin.org 5have been small-scale and likely underpowered and results have
been inconsistent, for instance for KIR2DS1 and for KIR3DL1. In
this study, we have overcome the sample size limitations due to
the relatively high cost of HLA and KIR genotyping by imputing
HLA alleles and KIR CN into existing GWAS datasets, a strategy
which we show can be cost-effective for groups wishing to
investigate the role of HLA and KIR in other conditions, using
large GWAS datasets such as the UK Biobank and other
forthcoming databases that will be available to researchers. In
addition to confirming that HLA-C2 as well as HLA-Bw4 are
associated with psoriasis, we have shown that with respect to KIR
CN, no KIR gene alone is associated with psoriasis. However, we
have shown that in the presence of both its cognate ligands HLA-
C1 and HLA-C2, KIR2DL2 copy number is associated with
psoriasis. At the time of this study, we are the first to report an
association of KIR2DL2 with psoriasis.
KIR CN Alone Is Not Associated
With Psoriasis
In this study, we observed that imputed KIR CN alone is not
sufficient to affect psoriasis risk, not even previously implicated KIR
genes such as KIR3DL1 and KIR2DS1. It is possible that KIR alleles
and allotypes are associated with psoriasis risk but KIR CN alone is
not sufficient to account for psoriasis risk. Even more importantly,
due to the lack of genetic linkage between KIR (chromosome 19)
and HLA (chromosome 6), the effect of KIR CN might not be
observed in the absence of its cognate HLA ligand. According to
Moesta and Parham (35), many individuals with a given KIR gene
may lack the cognate HLA class I ligand because co-evolution of
KIR with HLA class I does not necessarily lead to pre-disposing
combinations of HLA and KIR being inherited together.FIGURE 3 | HLA-C2 and HLA-Bw4 are associated with psoriasis. Plot of ORs estimated from the dominant HLA model adjusted for HLA-C*06:02 and the top 10 PCs.TABLE 2 | Known interactions between KIR and HLA ligands.
KIR HLA Ligand Recent Citations
2DL1 HLA-C2 Winchester et al. (30), Yawata et al. (31), Campbell et al. (32), Parham et al. (33)
2DL2 HLA-C1 and HLA-C2 Martin et al. (34), Campbell et al. (32), Moesta et al. (35), Parham et al. (33), David et al. (36), Chandran et al. (37)
2DS1 HLA-C2 Luszczek et al. (38), Suzuki et al. (39), Holm et al. (40), Campbell et al. (32), Parham et al. (33)
2DS4 HLA-C1, HLA-C2 Hsu et al. (41), Maxwell et al. (42), Campbell et al. (32), Parham et al. (33)
3DL1 HLA-Bw4 Cella et al. (43), Campbell et al., (32), Parham et al. (33), Ahn et al. (14), Berinstein et al. (15)
3DS1 HLA-Bw4-80T Campbell et al. (32), Parham et al. (33)June 2021 | Volume 12 | Article 684326
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With HLA-C1/C2 Have Increased Risk
for Psoriasis
While previous studies have implicated KIR2DS1 as a significant
factor in the pathogenesis of psoriasis, we did not observe a
significant association between KIR2DS1 copy number and
psoriasis, either alone or in the presence of its HLA ligand,
HLA-C2. However, when we stratified for HLA-C1/C2
heterozygous individuals, we observed a significant increase in
risk for psoriasis for individuals harboring two copies of
KIR2DL2, a result that remained true even after adjusting for
the effect of the canonical psoriasis high-risk alleles, HLA-
C*06:02 (a C2 allele) and HLA-C*12:03 (a C1 allele). In
addition to replicating this finding in the KP cohort, we also
observed that amongst individuals with HLA-C1/C2, having justFrontiers in Immunology | www.frontiersin.org 6one copy of KIR2DL2 significantly increased risk of psoriasis [OR
1.17 (95% CI 1.03-1.33)], indicating a dose-response
relationship. Finally, our meta-analysis of the PAGE+ and KP
cohorts confirmed that there is an elevated risk for developing
psoriasis in individuals that carry one or two copies of KIR2DL2
and are HLA-C1/C2 heterozygotes.
There are several possible interpretations of our findings.
Psoriasis is caused by a combination of factors involving the
adaptive and innate immune system (45). With regards to the
innate immune system, natural killer (NK) cells have been found
to play a role in the regulation of immune-mediated and
autoimmune disorders such as psoriasis. Several studies have
shown reduced cell cytotoxicity and increased interferon-gamma
production in NK cells from psoriatic patients compared to
healthy controls (46–48). In the autoimmune disorder multipleFIGURE 5 | Having one or two copies of KIR2DL2 is associated with psoriasis in the KP cohort when stratifying by HLA-C1/C2 after adjustment for HLA-C*06:02
and HLA-C*12:03. Plot of ORs from the KIR2DL2 model adjusted for HLA-C*06:02 and HLA-C*12:03 as well as the top 10 PCs.FIGURE 4 | Having two copies of KIR2DL2 is associated with psoriasis in the PAGE+ cohort when stratifying by HLA-C1/C2 after adjustment for HLA-C*06:02 and
HLA-C*12:03. Plot of ORs from the KIR2DL2 model adjusted for HLA-C*06:02 and HLA-C*12:03 as well as the top 10 PCs.June 2021 | Volume 12 | Article 684326
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activity, suggesting that in certain autoimmune disorders NK
cells may play an immunoregulatory role (49). While the
mechanism of this immunoregulation by NK cells is not yet
clear, it is likely that NK cell education plays an important role.
The NK cell education model proposes that the threshold for NK
cell activation and sensitivity to inhibition by self-MHC on
autologous cells are on an allelic gradient. In this model,
“uneducated” NK cells expressing inhibitory KIR without
corresponding HLA ligands on autologous cells have the
highest threshold for activation and the lowest sensitivity to
inhibition by self-MHC, while “highly educated” NK cells that
are homozygous for inhibitory KIR and the corresponding HLA
ligands have the lowest threshold for activation and the highest
sensitivity to inhibition by self-MHC (50). As such, the increase
in psoriasis risk that we observed in the PAGE+ and KP cohorts
for individuals with two copies of KIR2DL2 and HLA-C1/C2
may be due to the NK cells in these individuals being in an
intermediary education state whereby their activation threshold
is just high enough to lead to a dysregulated state.
Compared to NK cells, it is more firmly established that T
cells play a critical role in the initiation and maintenance of
psoriasis. Recently, the role of CD8+ T cells has gathered
attention (51–53), as these cells, along with their CD4+ T cell
counterparts, secrete the pathogenic cytokine, IL-17.
Interestingly, CD8+ T cells also express KIRs and it has been
shown that CD8+ T cell survival after activation is partially
dependent on expression of inhibitory KIRs. As noted by Seich al
Basatena et al. (54), the inhibitory KIR2DL2 may act by either
directly regulating NK cell mediated immunity or by regulating T
cell mediated immunity. A follow-up study by Boelen et al. (55)
that included both in-vitro CD8+ T cell survival data and HLA-
KIR genetic data concluded that inhibitory KIRs directly regulateFrontiers in Immunology | www.frontiersin.org 7T cell mediated immunity by increasing CD8+ T cell survival.
While terminally differentiated CD8+ T cells stochastically
express KIRs, Björkström et al. (56) have shown that most
individuals exhibit a narrow repertoire of KIR typically
dominated by one KIR gene. Interestingly, they also showed
that the specificity of inhibitory KIR genes on CD8+ T cells is
distinct from that of KIR genes expressed on NK cells from the
same individual, suggesting the possibility that a dominant KIR
gene (i.e. KIR2DL2) expressed on the surface of CD8+ T cells
may not be expressed on NK cells from the same individual.
Given that the studies over the last decade have provided much
more consensus on the direct role of CD8+ T cells on psoriasis
initiation and maintenance (9, 51) than NK cells (48, 57), it is
possible that carriers of KIR2DL2 are at greater risk for
developing psoriasis because those individuals are more likely
to have enhanced survival of skin resident memory CD8+ T cells
that can be activated by dendritic cells and release cytokines such
as IL-17.
However, it is not entirely clear at present whether having two
copies of KIR2DL2 and having HLA-C1/C2 principally drive NK
cell dysfunction due to incomplete NK cell education, increased
survival of potentially pathogenic CD8+ T cells, or both
mechanisms acting in concert to increase risk of developing
psoriasis. Future in-vitro studies of NK cell dysfunction and
CD8+ T cell survival from individuals with psoriasis that are
homozygous for inhibitory KIR and heterozygous for the
respective HLA ligands may shed more light. Finally, as KIR2DS2
is in near complete linkage disequilibrium with KIR2DL2, we
cannot rule out the possibility that the observed association
between KIR2DL2 CN and psoriasis may in part be due to the
presence of KIR2DS2. However, it should be noted that HLA-C1
and HLA-C2 are not thought to be ligands for KIR2DS2 (58). Our
future studies of KIR CN may also investigate the role of KIR2DS2.A
B
FIGURE 6 | Meta-analysis shows KIR2DL2 is associated with psoriasis. (A) Meta-analysis of model with 2 copies of KIR2DL2, stratified on HLA-C1/C2, and
adjusted for HLA-C*0602, HLA-C*12:03, and the first 10 principal components (PCs). (B) Meta-analysis of model with 1 copy of KIR2DL2, stratified on HLA-C1/C2,
and adjusted for HLA-C*0602, HLA-C*12:03, and the first 10 PCs.June 2021 | Volume 12 | Article 684326
Ahn et al. Imputed KIR2DL2 Association With PsoriasisKIR3DL1 and HLA-Bw4-80I
In a previous small-scale study (14), we showed that the low and
null allotypes of KIR3DL1 are associated with increased and
decreased risk for psoriasis, respectively. We also showed that
KIR3DL1 low in combination with HLA-Bw4 significantly
increases risk for psoriasis. In the present study we discovered
that KIR3DL1 copy number alone is not significantly associated
with psoriasis while HLA-Bw4 and HLA-Bw4-80I were both
significantly associated with psoriasis, even after adjusting for the
known high-risk allele HLA-C*06:02. Furthermore, we observed
that KIR3DL1 copy number in models stratified on HLA-Bw4 or
HLA-Bw4-80I were not significantly associated with psoriasis. It
is possible that a significant association was not observed because
KIR3DL1 copy number does not account for whether cell surface
expression of KIR3DL1 will be low, high, or null. Our future
efforts include developing an update to KIR*IMP to impute not
only KIR CN, but also KIR alleles. Imputation of KIR alleles will
allow us to develop models that include allotypes of KIR3DL1 (or
any other KIR gene that we can successfully impute).
Limitations
While this present work has only tested imputed KIR CN for
association with psoriasis, we hope to test imputed KIR alleles in
the near future after updates to the current version of KIR*IMP
are implemented. Testing imputed KIR alleles will allow for
replication of previous KIR allelic associations, such as the
protective effect of KIR3DL1 Null (14, 15). While this present
study includes samples from individuals of European descent,
future studies may also include samples from individuals of
African American and East Asian descent.
Conclusions
While previous studies of the role of KIR genes have been limited
by small sample sizes, we have implemented state-of-the-art
imputation methods to impute KIR CN and HLA alleles into
thousands of samples from previous GWAS. Our results show
that HLA-C1/C2 heterozygous carriers with 2 copies of KIR2DL2
are at an elevated risk for developing psoriasis.DATA AVAILABILITY STATEMENT
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